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Abstract Cystinosis is the major cause of inherited
Fanconi syndrome, and should be suspected in young
children with failure to thrive and signs of renal proximal
tubular damage. The diagnosis can be missed in infants,
because not all signs of renal Fanconi syndrome are present
during the first months of life. In older patients cystinosis
can mimic idiopathic nephrotic syndrome due to focal and
segmental glomerulosclerosis. Measuring elevated white
blood cell cystine content is the corner stone for the
diagnosis. The diagnosis is confirmed by molecular
analysis of the cystinosin gene. Corneal cystine crystals
are invariably present in all patients with cystinosis after the
age of 1 year. Treatment with the cystine depleting drug
cysteamine should be initiated as soon as possible and
continued lifelong to prolong renal function survival and
protect extra-renal organs. This educational feature provides
practical tools for the diagnosis and treatment of cystinosis.
Keywords Cystinosis.Cystinosin.Renal Fanconi
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Introduction
During the last few decades, significant progress has
been made in elucidating the genetic background and
pathogenesis of numerous metabolic disorders, allowing
earlier diagnosis and better treatment. However, because
many of these disorders are relatively rare and can have
various presentations, recognizing them in patients still
poses problems. Furthermore, individual physicians fre-
quently lack experience in adequate management of the
patients. The objective of this teaching article is to
provide pediatric nephrologists with practical tools for
the diagnosis and treatment of nephropathic cystinosis.
The pathogenesis of cystinosis, which is still not
completely elucidated, remains beyond the scope of this
review.
Definition and clinical forms of cystinosis
Cystinosis is an autosomal recessive disorder characterized
by an accumulation of the amino acid cystine in lysosomes
throughout the body. The responsible gene CTNS, encoding
the lysosomal cystine carrier cystinosin, has been cloned in
1998 and is located on the short arm of the chromosome 17
(p13) [1, 2].
Depending on the age at presentation and the degree of
disease severity, three clinical forms of cystinosis are
distinguished:
1. Nephropathic infantile form (MIM #219800), which is
the most frequent and most severe form of the disease
2. Nephropathic juvenile form (MIM #219900); syno-
nyms: intermediate cystinosis, late-onset form, adoles-
cent form
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All three forms of the disease are caused by mutations of
the CTNS gene and have phenotypic overlap.
Clinical presentation of renal disease in cystinosis
Nephropathic infantile cystinosis
Patients with infantile cystinosis are generally born from
uneventful pregnancies and have normal birth weight and
length. Despite cystine accumulation starting in utero,
clinical symptoms are absent at birth and gradually develop
during the first months of life. The kidneys are the first
affected organs, and progressively lose function of their
proximal tubular transporters, resulting in urinary loss of
water, Na
+,K
+, bicarbonate, Ca
2+,M g
2+, phosphate, amino
acids, glucose, proteins, and many other solutes reabsorbed
in this nephron segment. This generalized proximal tubular
dysfunction is called “deToni–Debré–Fanconi syndrome”
or “renal Fanconi syndrome” for short, named after the
pediatricians who first described the disorder in the last
century [3]. Asymptomatic aminoaciduria can already
appear during the first weeks of life and is followed by
glucosuria, phosphaturia, and urinary bicarbonate losses
during the first months of infancy [4, 5]. In one sibling of a
known patient with cystinosis, longitudinally followed from
birth, the excretion of the low molecular weight (LMW)
protein alpha-1 microglobulin was increased only at the age
of 6 months [5]. This observation indicates that diverse
proximal tubular transporters have differential sensitivity
to cystinosin dysfunction, and that the diagnosis of
cystinosis can be missed during the first months of life,
especially when only a limited number of urinary
markers are used to identify renal Fanconi syndrome.
At the age of 6 months, full-blown Fanconi syndrome is
usually present and causes clinical symptoms of polyuria,
thirst, failure to thrive, growth retardation, vomiting,
periods of dehydration, constipation, developmental
delay, and rickets in some patients. Biochemically, the
patients present with hypokalemia, hypophosphatemia,
metabolic acidosis, low serum uric acid, low carnitine,
and, sometimes, hyponatremia [2]. Occasionally, hypoka-
lemia in combination with hypochloremic metabolic
alkalosis and elevated plasma renin activity can mimic
Bartter syndrome [6, 7]. Proteinuria can reach grams per
day, and consists of LMW proteins, albumin, and high
molecular weight proteins [8]. Excessive losses of calcium
and phosphate can cause the development of nephrocalci-
nosis and the formation of renal stones [9].
Because the clinical condition of most patients remains
quite satisfactory for several months and not all character-
istic symptoms are present in the same young patient, the
current approach of adapting the feeding scheme and
screening for malabsorption syndromes or food allergy
frequently results in several months' delay in correct
diagnosis.
In most patients the glomerular filtration rate (GFR)
remains normal for up to 2 years and then progressively
deteriorates towards end stage renal disease (ESRD) at the
end of the first decade [10].
Both hemodialysis and peritoneal dialysis are suitable
for renal replacement therapy (RRT) in cystinosis patients.
The choice for the dialysis mode is made comparably to
patients with other renal disorders.
Renal transplantation is the treatment of choice in
patients with ESRD, as the disease does not recur in the
grafted organ. Cystine crystals can be observed in graft
biopsies, but are originating from the host mononuclear
cells, and are of no pathological value [11]. Two indepen-
dent studies demonstrated superior renal graft survival in
cystinosis, compared with other renal diseases [12, 13].
However, analyzing data from the ERA-EDTA registry
failed to demonstrate this advantage [14]. Renal Fanconi
syndrome can persist after initiation of dialysis or after
renal transplantation, but only rarely necessitates a nephrec-
tomy of the native kidneys, because excessive fluid and
electrolyte losses generally decrease during RRT.
Nephropathic juvenile form
The nephropathic juvenile form of the disease is diagnosed
in the minority of the patients (~5%) and manifests with a
spectrum of symptoms, varying from milder (compared
with the infantile form) proximal tubulopathy to an
apparent nephrotic syndrome [2, 15]. In terms of the age
at presentation, there is a continuum between the infantile
and the late-onset form; however, most of the patients
described were older than 10 years. The deterioration of
renal function also occurs in the late-onset form, but the
rate of renal disease progression is mostly slower compared
with the infantile form of cystinosis.
Non-nephropathic adult form
Ocular non-nephropathic cystinosis manifests only with
complaints of photophobia due to cystine accumulation
in the cornea of the eye, which is also present in
nephropathic cystinosis. The kidney, retina, and other
organs are spared in these patients [16, 17]. Recently, the
coexistence of juvenile and ocular forms of cystinosis was
described in one family [18], suggesting that there might
be a continuum between mild forms of cystinosis and thus
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adult cystinosis.
Renal pathology
Renal biopsy is not required for the diagnosis of cystinosis,
and therefore the descriptions of renal histology at early
stages of the disease are limited. Serial renal biopsy in 2
cystinosis patients demonstrated an atrophy of the proximal
convoluted tubules, called a “swan neck deformity”, which
appeared after 6 months of life [19]. In a larger series of
kidney specimens the most striking features were the
irregularities of the tubular brush border and very large
cells with a prominent and hyperchromatic cytoplasm [20].
Cystine crystals are mostly seen within the interstitial cells
and rarely in the podocytes, but not in the tubular cells. Giant
multinucleated podocytes and parietal epithelial cells are
frequently observed and are pathognomonic for the disorder
[21]. Electron microscopy demonstrates podocyte foot
process retraction, especially in patients with pronounced
proteinuria [8].
The deterioration of renal function is accompanied by
progressive tubulo-interstitial and glomerular lesions, con-
sisting of interstitial fibrosis, tubular atrophy, segmental or
global collapsing of the glomerular tuft and an accumula-
tion of mesangial matrix material [20].
Renal histology in patients with late-onset cystinosis
may demonstrate glomerular lesions, undistinguishable
from idiopathic focal and segmental glomerulosclerosis
(FSGS) [18], and therefore the diagnosis can be missed in
older patients presenting with nephrotic syndrome.
Extra-renal symptoms of cystinosis
Eye involvement
Corneal cystine crystals are absent at birth and generally
can be observed by an experienced ophthalmologist with
slit lamp examination at the age of 1 year. These crystals
cause reflections of light and result in photophobia with
substantial discomfort. Untreated teenagers may develop
painful corneal erosions, punctate, filamentous or band
keratopathy, iris crystals, and peripheral corneal neovascu-
larization [22, 23]. The degeneration of the retinal pigment
epithelium, resulting in patchy depigmentation of the retina
(beginning in the periphery and extending in time), may
cause visual impairment mostly starting from the second
decade of life [24]. However, retinal epithelium vacuoliza-
tion has already described in an 18-week-old fetus and
fundoscopic retinal changes were observed in two siblings
with cystinosis as early as 5 and 10 weeks of age [25, 26].
Endocrine organ involvement
The continuing multi-organ accumulation of cystine crys-
tals leads to impairment of endocrine organs. Hypothyroid-
ism is found in up to 70% of untreated cystinosis patients
older than 10 years [27]. Impaired insulin production can be
exacerbated by steroid therapy after renal transplantation
and results in insulin-dependent diabetes mellitus [28].
Puberty generally proceeds normally in females, and
several have given birth. Males may have primary
hypogonadism and do not always complete pubertal
development [29]. So far, no male cystinotic patients are
known to have induced pregnancy, even while under
adequate cysteamine treatment. Recently, azoospermia was
demonstrated in cystinotic males treated with cysteamine,
although spermatogenesis was observed in a testis biopsy of
one patient, opening new possibilities for in vitro fertiliza-
tion [30].
Central nervous system and muscle involvement
Two major types of cystinotic encephalopathy, developing
predominantly during the third decade of life, are distin-
guished: encephalopathy presenting with cerebellar and
pyramidal signs, mental deterioration and pseudo-bulbar
palsy; or encephalopathy associated with stroke-like epi-
sodes [31]. The most common imaging finding in these
patients is cerebral cortical atrophy, as visualized by
computed tomography (CT) [32]; however, non-absorptive
hydrocephalus, demyelinization of the internal capsule and
brachium pontis, mineralization of the hemispheres and
basal ganglia have also been reported [33]. Moreover,
benign intracranial hypertension presenting with headaches
and papilledema has been described as well [34]. Although
general intelligence is normal in cystinosis patients, an
alteration of specific neurocognitive functions such as
visual–motor integration, visual memory, sustained atten-
tion, planning, and motor speed have been observed [35].
These intellectual deficits are present already in young
children and are suggested to originate from a develop-
mental abnormality of the cerebral white matter [36].
Vacuolar myopathy, resulting from excessive cystine
accumulation in the muscle, manifests generally after the
10th birthday [37]. Patients suffer from progressive
muscle wasting and reduced strength with restrictive
ventilatory defects [38]. High prevalence of swallowing
difficulty (>50%), including oral, pharyngeal and esoph-
ageal swallowing phases, has been recently reported in a
study population of 101 patients with cystinosis aged 6 to
45 years [39]. The severity of swallowing dysfunction had
a direct relation to the severity of muscular disease and
decreased with the number of years on cysteamine therapy
[39].
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Other reported extra-renal symptoms include decreased skin
and hair pigmentation (in patients of European descent),
impaired sweating, exocrine pancreas deficiency, portal
hypertension, hypersplenism and cystinotic bone disease [2,
38]. The latter is multifactorial in nature and is attributed to
losses of calcium, phosphate, and vitamin D, cystine
accumulation in the bone, and uremic osteodystrophy [40].
Notably, dual-energy X-ray absorptiometry (DEXA) does
not predict the risk of fractures in cystinosis patients possibly
due to false elevation of bone mineral composition by bone
cystine crystals [41].
Patients of African or Middle Eastern origin can have dark
hair and dark skin, which should not exclude the diagnosis.
Diagnosis of cystinosis
A flow chart that can be used for the diagnosis and
subsequent follow-up of patients with cystinosis is
presented in Fig. 1. Cystinosis should be suspected in all
patients with failure to thrive and signs of renal Fanconi
syndrome, as it is the most common cause of inherited
Fanconi syndrome in children. The detection of elevated
intracellular cystine content is the cornerstone for the
diagnosis. The methods for cystine determination differ
depending on the cell type: mixed leukocyte preparation or
polymorphonuclear (PMN) leukocytes. Furthermore, sev-
eral biochemical methods are currently used for cystine
measurement, such as a cystine-binding assay, amino acid
chromatography or high performance liquid chromatogra-
phy, making it difficult to compare the results of different
laboratories [42–44]. In our opinion, cystine measurement
should be performed in isolated PMN leukocytes, as these
cells preferentially accumulate cystine in blood. This
method increases the sensitivity of cystine detection
during the monitoring of cysteamine treatment [45]. The
cystine-binding assay has been a gold standard for cystine
measurements for years; however, at present, most labora-
tories have switched to the other methods of detection,
because of lower price and avoidance of radioactivity. In
this respect, tandem mass spectrometry (tandem MS) is the
most sensitive method and is currently widely used for
cystine determination in cystinosis [46]. Each laboratory
performing cystine measurements should provide their own
reference values in patients at the time of diagnosis, and
also for heterozygote and healthy subjects. Reference
values, provided by our laboratory are indicated in Fig. 1.
In Europe, the quality of cystine measurements in individ-
ual laboratories is monitor e db yE R N D I M( E u r o p e a n
Research Network for evaluation and improvement of
screening, Diagnosis and treatment of Inherited disorders
of Metabolism) [47].
Molecular analysis of the cystinosin gene allows early
diagnosis and can be used for prenatal diagnosis of the
disease. Prenatal diagnosis of cystinosis can also be made
by measuring
35S-labeled cystine accumulation in cultured
amniocytes or chorionic villi samples (CVS); and by a
direct measurement of cystine in uncultured CVS [48].
Since the cloning of CTNS in 1998, over 90 mutations have
been reported, with a detection ratio close to 100% [49–53].
The most common mutation accounting for approximately
75% of the affected alleles in Northern Europe is a 57-kb
deletion, affecting the first 10 exons of CTNS, the 5’ region
upstream encoding the CARKL gene [50] and the first two
non-coding exons of TRPV1. While renal phenotype in
infantile cystinosis is comparable between patients with
homozygous 57-kb deletion and those with other truncating
mutations, this is unknown with regard to extra-renal
phenotype. A genotype–phenotype correlation related to
the clinical forms of cystinosis is observed, with severe
truncating mutations mostly found in patients with the
infantile form of the disease and at least one mutation
allowing the residual function of cystinosin in patients with
intermediate or adult cystinosis. However, several unex-
plained exceptions were reported [54].
Differential diagnosis
Cystinosis should be distinguished from other inherited
causes of renal Fanconi syndrome, which are summarized in
Table 1. After1yearofage,theobservationofcystinecrystals
in the cornea is pathognomonic for cystinosis, whereas the
absence of the crystals excludes the diagnosis after the age of
2 years. Patients with the juvenile form of cystinosis also
invariably demonstrate corneal cystine crystals.
It is noteworthy that a second lysosomal cystine storage
disease, namely mucolipidosis type II, or I-cell disease, has
been identified [55]. Clinical symptoms are very heteroge-
neous, but usually include dwarfism, coarse facial features,
and mental retardation [56]. Additionally, proximal tubular
dysfunction was reported with LMW proteinuria, aminoac-
iduria, hyperphosphaturia, and high urinary calcium excre-
tion [57]. This autosomal recessive disorder is caused by a
deficiency of N-acetylglucosamine-1-phosphotransferase,
resulting in defective mannose-6-phosphorylation [58]. As
a consequence, lysosomal enzymes are not transported to
the lysosomes upon post-translational modification in the
Golgi apparatus. Similar to cystinosis, lysosomal cystine
levels are elevated in fibroblasts isolated from patients with
I-cell disease, but hepatic or white blood cell cystine levels
are within the normal range [59].
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tant presence of symptoms of proximal tubular dysfunction
such as aminoaciduria, glucosuria, and phosphaturia should
not allow the diagnosis of cystinosis to be missed. Patients
with intermediate cystinosis presenting with pronounced
proteinuria and FSGS in renal biopsies can be easily
overlooked. Eye examination demonstrating corneal cystine
crystals and possibly mild tubulopathy should point to the
diagnosis of cystinosis in these patients.
Treatment
Life style matters
All patients with cystinosis should have free access to water
and toilet, because of pronounced polyuria and polydipsia.
Prolonged exposure to heat and sun should be avoided
because of photophobia, the risk of dehydration and/or heat
stroke due to impaired sweating.
Clinical suspicion of 
cystinosis
- Failure to thrive, growth retardation
- Vomiting, constipation
- Thirst, polyuria
- Rickets
- Pale skin and hair color (in patients of 
European descent)
- Urine and serum biochemistry      
parameters: hypokalemia
hypophosphatemia
metabolic acidosis
low serum uric acid
glucose wasting
proteinuria
1 Making the diagnosis
- Determination of elevated cystine 
levels in PMNs
- Eye examination (corneal crystals)
- Confirmation by CTNS gene   
analysis
PMN cystine levels*: 
(nmol cystine/mg protein**)
- In healthy subjects: 0.04-0.16 
- In heterozygotes: 0.14-0.57
- In patients at diagnosis: > 1
Fibroblasts’ cystine levels***:
- In healthy subjects: 0-0.23 
- In patients at diagnosis: > 2.5
Follow-up of children:
4 times a year outpatient clinic 
to monitor/treat:
- Growth, nutrition
- Biochemical abnormalities due to 
Fanconi syndrome 
- Renal function assessment
- PMN leukocyte cystine levels/
cysteamine dose adaptation
- At the end of 1st decade: extra-renal 
involvement (thyroid function, glucose 
tolerance, gonadal function)
At least once a year: 
- Eye examination
Before primary and secondary
school:  
- Neurocognitive testing
Follow-up of adults&
At least once a year outpatient clinic 
to monitor /adapt:
- PMN leukocyte cystine levels/ 
cysteamine dose
- Eye examination
- Endocrinologic examination (thyroid, 
pancreas, gonades)
- Neurologic/muscular examination
- Advise regarding social and 
professional items
transition
* Values providedby Laboratory of Genetic Endocrine and Metabolic Diseases, Radboud University 
Nijmegen Medical Centre, The Netherlands(Dr. L. Kluijtmans)
** In the literature cystine is frequently expressed as ½ cystine/mg protein. 
½ cystine/mg protein = 2 x cystine/mg protein 
*** Cystine measurements in cultured fibroblasts can be used for the confirmation of the diagnosis, 
when molecular analysis of the CTNS gene is not available.
& Most adult patients are transplanted and are followed by adult nephrologists; the scheme of 
nephrologicfollow-up is not included in this figure.
2
34
Fig. 1 Flowchart for the
diagnosis and follow-up of
patients with cystinosis
Pediatr Nephrol (2011) 26:205–215 209Symptomatic therapy
The aim of symptomatic therapy in patients presenting with
Fanconi syndrome is the maintenance of fluid and electrolyte
balance, good nutrition and prevention of rickets. The
dose of potassium, sodium, bicarbonate, and phosphate
varies substantially and shall be regularly adapted
according to serum values. 1,25-dihydroxycholecalciferol
supplementation should be used starting from early
childhood [60]. However, excessive administration of
phosphate, 1,25-dihydroxycholecalciferol and bicarbonate
may aggravate the development of nephrocalcinosis or
stimulate renal stone formation [60, 61]. Calcium supple-
mentation is generally not indicated. Carnitine replace-
ment normalizes plasma and muscular carnitine levels;
however, it is not established whether carnitine adminis-
tration results in improved muscular performance [62, 63].
Poor appetite, vomiting, and oral motor dysfunction
often require a nasogastric tube or gastrostomy feeding,
especially in young children [64, 65]. Treatment with
recombinant growth hormone results in catch-up growth
and further maintenance of growth velocity [66]. Growth
hormone is frequently not required in patients treated with
cysteamine, especially when started at an early age, as
cysteamine by itself improves growth [67].
Other complications, such as hypothyroidism, diabetes,
or hypogonadism, are considered for treatment with
levothyroxin, insulin, and testosterone respectively.
Inhibition of the renin–angiotensin system (RAS) results
in a decrease of albuminuria in cystinosis [68]; however,
this class of drugs should be used with caution, because of
the risk of hypotension and renal function decline in
cystinosis patients already suffering from extracellular
volume and/or salt depletion.
Table 1 Causes of renal Fanconi syndrome to be considered for differential diagnoses of cystinosis
Disorder (OMIM) Gene Inheritance Protein Key clinical/biochemical features
ARC syndrome VPS33B autosomal recessive Vps33 Arthrogryposis, cholestasis, dysmorphic features,
ichtiosis, abnormal platelets, severe infections
Cystinosis CTNS autosomal recessive Cystinosin Failure to thrive, rickets, metabolic, acidosis,
renal failure, photophobia
Dent’s disease
a CLCN5 X-linked recessive Chloride channel 5 LMW proteinuria, hypercalciuria,
nephrocalcinosis, nephrolithiasis, renal failure
Fanconi–Bickel
syndrome
SLC2A2 autosomal recessive Facilitative glucose
transporter 2 (GLUT2)
Hepatorenal glycogen accumulation,
hepatomegaly, rachitic and osteomalacia, mental
retardation
Galactosaemia GALT autosomal recessive Galactose-1-phosphate-
uridyl-transferase
Hepatomegaly, liver disease, cataract, mental
retardation
Glycogen Storage
Disease Type 1
G6PC autosomal recessive Glucose-6-phosphatase Hypoglycemia, lactic acidosis and
hyperlipidemia, hepatomegaly
Hereditary fructose
intolerance
ALDOB autosomal recessive Aldose B Fructose intolerance, growth retardation
I-cell disease
(mucolipidosis II)
GNPTAB autosomal recessive N-acetylglucosamine-1-
phosphotransferase
Dwarfism, contractures of large joints, coarse
facial features, thickend skin and mucosae,
mental retardation
Idiopathic Fanconi
syndrome
Unknown autosomal dominant
autosomal recessive
Unknown Isolated Fanconi syndrome
Lowe syndrome
a OCRL1 X-linked recessive Phosphatidyl-inositol
4,5-biphosphate-
5-phosphatase
Short stature, congenital cataract, mental
retardation, seizures, cryptorchidism,
arthropathy, elevated transaminases and
creatine kinase
Metachromatic
leukodystrophy
ARSA;
PSAP
autosomal recessive Arylsulfatase A;
Prosaposin
Muscle wasting and weakness, spasticity,
developmental regression
Mitochondrial disease
b Diverse Diverse Diverse Diverse
Tyrosinaemia FAHD2A autosomal recessive Fumaryl-acetoacetate
hydrolase
Glomerulosclerosis, nephrocalcinosis,
hepatomegaly, cirrhosis, rickets,
growth retardation
Wilson disease ATP7B autosomal recessive Copper-transporting
ATPase (β subunit)
Kayser–Fleischer rings (cornea), hepatitis,
cirrhosis CNS abnormalities
aGlucosuria can be absent
bPatients with mitochondrial diseases can present with Fanconi syndrome. Among other reported genes, affected proteins involve cytochrome C oxidase,
phosphoenolpyruvate carboxykinase or Acyl-CoA dehydrogenase
210 Pediatr Nephrol (2011) 26:205–215Specific treatment with cysteamine
The amino thiol cysteamine depletes lysosomal cystine
content by a disulfide exchange reaction with cystine,
resulting in the formation of cysteine–cysteamine mixed
disulfide and cysteine (Fig. 2). Cysteine–cysteamine mixed
disulfide exits lysosomes via a “system c” transporter and
the remaining cysteine via a cysteine carrier. The adminis-
tration of cysteamine at 1.3–1.9 g/m
2 in four daily doses
drastically lowers the cystine content of the lysosomes,
postpones or even prevents the deterioration of renal
function and the development of extra-renal complications
[69, 70]. Furthermore, cysteamine treatment improves
growth [71]. Cysteamine should be administered as soon
as the diagnosis of cystinosis is made, and continued
lifelong, even after renal transplantation to protect the extra-
renal organs.
The side effects of cysteamine are mostly restricted to
gastrointestinal discomfort (due to the release of gastrin
and the resulting stimulation of H
+ secretion in the
stomach [72]), and bad breath and sweat odor (due to
formation of dimethylsulfide and methanethiol, which are
metabolites of cysteamine [73]). Gastric acid hypersecre-
tion and ulcerogenicity of cysteamine can be improved by
the administration of proton pump inhibitors [70]. Allergic
reactions, fever, seizures, and neutropenia are also
reported, especially when the dose of the drug is
abruptly increased. Recently, 8 European patients treated
with high cysteamine doses were reported to exhibit
endothelial proliferative lesions on the elbows, skin
striae, and bone and muscular pain, which improved or
disappeared after lowering the cysteamine dosing (per-
sonal communication from Orphan Europe). Because of
these adverse events, using cysteamine doses above the
recommended 1.9 g/m
2 should be discouraged. Cyste-
amine dose calculation per kg body weight (60–90 mg/kg/
day) results in dosing above the recommended range in
children > 20 kg.
As the target tissue cystine levels necessary to prevent
the progression of renal disease and the occurrence of
extra-renal complications are still unknown, the 0.9
percentile of heterozygote values in the PMN cells is
mostly recommended as an upper cystine limit before the
next dose of cysteamine is given (<0.5 nmol cystine per
mg protein) [74]. Because leukocyte cystine content
returns to the initial high levels 6 h after cysteamine
administration [75] ,t h ed r u gs h o u l db et a k e ne v e r y6h
including through the night [76]. For monitoring cyste-
amine therapy blood should be drawn 6 h after the last
intake of the drug. The current development of enteric-
Fig. 2 Cystine depleting action of cysteamine. In the left panel, a
normal lysosome is presented; cystine located in the lysosomes is
exported via cystinosin. In the cytosol, cystine is reduced to two
cysteine residues. The middle panel shows a cystinotic lysosome,
where cystinosin is absent (or dysfunctional), resulting in increased
levels of lysosomal cystine. Upon cysteamine treatment in the
cystinotic lysosome, cystine is degraded into cysteine and cysteine–
cysteamine, as presented in the right panel. Both degradation products
can be exported via cysteine and as yet unidentified “system c”
transporters, encompassing the defective cystinosin
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compliance with cysteamine therapy and improve the
quality of life, when its efficiency and safety have been
confirmed in ongoing clinical trials [77].
The regular measurements of cystine in PMN leukocytes
are required in order to adjust cysteamine dose. Unfortunately,
in the majority of patients cysteamine cannot reverse Fanconi
syndromeandonlypostponesthedevelopmentofrenalfailure.
Cysteamine toxicity with the development of cleft palate
and kyphosis, as well as intrauterine growth retardation and
fetaldeath,withoutsignsofmaternaltoxicity,wasobservedin
rats treated with high cysteamine dose (100–150 mg/kg/day)
[78]. Although the effect in humans treated with lower doses
is unknown, it is generally recommended to discontinue
cysteamine in female patients who are planning a pregnancy.
Because systemic cysteamine treatment has no effect on
corneal cystine crystals, topical 0.5 % cysteamine eye drops
are indicated. These drops are highly effective and when
administered 6 to 12 times daily are able to dissolve corneal
cystine crystals completely within 8 to 41 months, even at a
later age [79]. Hopefully, commercially available cyste-
amine eye drops, gel formulation or ointment can be
developed to decrease the required frequency of application
and to improve compliance [80].
A recent pioneering study using CTNS-knockout mice
demonstrated a beneficial effect of syngeneic bone marrow
and hematopoietic stem cell transplantation on cystine
accumulation in various organs and on renal function
survival [81], emphasizing novel potential therapeutic
possibilities for cystinosis patients.
Follow-up of cystinosis patients
Follow-up recommendations for cystinosis patients, applied
in our institutions, are summarized in Fig. 1. Infants and
children with cystinosis who have renal Fanconi syndrome
should be examined frequently (at least four times a year) to
monitor growth and the nutritional state, metabolic control
of Fanconi syndrome, and white blood cell cystine
measurements for adapting cysteamine dose. Ophthalmic
control, including slit lamp examination and funduscopy, at
a minimum of once a year, is mandatory. Children in pre-
and school age should undergo neurocognitive testing to
detect specific deficiencies and to adapt the school program
(if required). Children after renal transplantation are usually
followed according to the rules in the transplantation clinic;
however, cystine measurements and eye examination
should be performed with the same frequency as in children
with renal Fanconi syndrome. Starting from the end of the
first decade of life, special attention should be paid to the
possible appearance of extra-renal complications. Adoles-
cents should be informed about the influence of cystinosis
on their sexual development and fertility. Qualified advice
regarding study and job choices should be performed by
psychologists and social workers. Transition to the adult
multi-disciplinary clinics, preferably experienced in treat-
ment of cystinosis patients, should be carefully prepared. In
stable adult patients, cystine white blood cells levels should
be monitored at least once a year. Additionally, yearly
check-ups by an ophthalmologist, endocrinologist, and
neurologist are required to monitor the extra-renal compli-
cations of the disease.
Take-home message
Despite the awareness of the medical community, the
diagnosis of cystinosis is frequently delayed, because of
the initial incomplete presentation and the rarity of the
disorder. In all patients presenting with failure to thrive
during the first years of life, renal Fanconi syndrome should
be excluded. The true diagnosis of cystinosis is based on
the measurement of elevated cystine content in blood cells,
and molecular analysis of the CTNS gene. Cysteamine is
currently the only available treatment interfering with the
disease pathogenesis; however, new treatment modalities
may become available in the future.
Multiple choice questions
Answers appear following the reference list
1. Prenatal diagnosis of cystinosis is possible by:
a) Measuring leukocyte cystine content in the mother
b) Measuring the
35S cystine accumulation in a
chorionic villi sample or cultured amniocytes
c) Molecular analysis of the CTNS gene in fetal tissue
d) Measuring alfa-fetoprotein in the amniotic fluid
2. In a newborn cystinosis can be diagnosed by:
a) Measuring leukocyte cystine content
b) Screening for symptoms of renal Fanconi syn-
drome (urinary excretion of LMW proteins, phos-
phate, amino acids, glucose)
c) Molecular analysis of the CTNS gene
d) Detection of cystine crystals in the cornea
e) All of the above
3. After making diagnosis of cystinosis, treatment with
cysteamine should be started:
a) Immediately upon confirmation of diagnosis
b) As soon as symptoms of renal Fanconi syndrome
are present
c) When GFR is decreased
212 Pediatr Nephrol (2011) 26:205–2154. After renal transplantation cysteamine treatment should be:
a) Discontinued, because of possible side-effects
b) Discontinued, because of interaction with immu-
nosuppressive treatment
c) Continued, but only if renal graft function is
decreased
d) Continued, to protect the extra renal-organs
5. An adolescent with cystinosis complains about the side-
effects of cysteamine medication (vomiting, bad odor,
frequent intake), because they interfere with his social
life. Therefore, he sometimes skips one of the intakes,
but uses a higher dose of cysteamine on the other
occasions. Given the circumstances, what is advisable?
a) Instead of four daily doses, divide the same
cysteamine dose over three intakes
b) Explain that cysteamine is active for only 6 h and
therefore should be taken four times daily. Occa-
sionally taking high doses increases the risk of
side-effects
c) Administer proton pump inhibitors to treat gastric
discomfort
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